MALVERN, Pa.--(BUSINESS WIRE)--Trice Medical announced today that it closed an $18.3 million Series C Extension financing round. The company will use the proceeds to expand their worldwide commercialization efforts for mi-eye 2™ and mi-ultra™ and to accelerate the development of their minimally invasive product portfolio.
This round was led by Charter Capital Partners of Grand Rapids, Michigan and the Municipal Employees’ Retirement System(MERS) of Michigan. Other investors in Trice include Safeguard Scientifics, Inc. (NYSE:SFE), HealthQuest Capital, BioStar Ventures and Smith & Nephew.
John Kerschen, Managing Partner of Charter Capital Partners, stated, “We have been tracking Trice’s progress for almost five years and are pleased to make this investment at this point in the Company’s growth. Trice has a unique value proposition in the market with its mi-eye 2™ platform and we see physicians from all over the country embracing the mi-eye™ as the preferred way to visualize potential orthopedic injuries in an office setting.” more